...
机译:idarucizumab作为Dabigatran在日常临床实践中的表现
Leiden Univ Med Ctr Dept Thrombosis &
Hemostasis Albinusdreef 2 NL-2300 RC Leiden Netherlands;
Leiden Univ Med Ctr Dept Clin Pharm &
Toxicol Leiden Netherlands;
Sint Maartens Klin Dept Pharm Nijmegen Netherlands;
Erasmus MC Dept Hematol Rotterdam Netherlands;
Univ Groningen Univ Med Ctr Groningen Dept Hematol Groningen Netherlands;
Haaglanden Med Ctr Dept Hematol The Hague Netherlands;
Catharina Hosp Dept Cardiol Eindhoven Netherlands;
Amphia Hosp Dept Cardiol Breda Netherlands;
Martini Hosp Dept Cardiol Groningen Netherlands;
Albert Schweitzer Hosp Dept Internal Med Dordrecht Netherlands;
Leiden Univ Med Ctr Dept Thrombosis &
Hemostasis Albinusdreef 2 NL-2300 RC Leiden Netherlands;
Leiden Univ Med Ctr Dept Thrombosis &
Hemostasis Albinusdreef 2 NL-2300 RC Leiden Netherlands;
Idarucizumab; Dabigatran; Bleeding; Reversal;
机译:idarucizumab作为Dabigatran在日常临床实践中的表现
机译:使用达比加群(idarucizumab)的特定解毒剂可降低达比加群引起的和创伤引起的猪出血的失血量和死亡率
机译:在手术期间错误给予Dabigatran解毒剂idarucizumab:案例报告和经验教训
机译:一种“动态-DDD(确定的每日剂量)监测”的方法,以减少不良的临床结果并提高患者安全性:临床实践中的信息库和事件触发因素
机译:直接实践改进项目-改善门诊大肠癌筛查的初级保健临床表现
机译:使用达比加群(idarucizumab)的特定解毒剂可减少达比加群引起的和创伤引起的猪出血的失血和死亡率
机译:使用达比加群(idarucizumab)的特定解毒剂可降低达比加群引起的和创伤引起的猪出血的失血量和死亡率